Abstract
Botulinum toxin (BT) represents one of the latest and most revolutionary treatments in facial rejuvenation. The cosmetic use of BT in the upper third of the face began in the late 1980s and gradually advanced to applications in the mid and lower face, neck and other areas of the body. Currently, more accurate techniques and the adjunctive use of BT allow physicians more precise applications, with significantly improved, more natural-looking results. Every year, the discoveries of many new clinical and cosmetic uses of BT continue to show the utility and versatility of this therapeutic modality, both in dermatology and in other specialized areas of medicine.
Financial disclosure
Doris Hexsel is a consultant, researcher and stockholder of IPSEN. She is also researcher and stockholder of Revance Therapeutics Inc., and she is researcher for Allergan. There was no industry support for the preparation and publication of this manuscript.